Teva Pharmaceutical Industries Ltd (ADR)  

(Public, NYSE:TEVA)   Watch this stock  
Find more results for TEVA
May 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range     -
52 week 47.36 - 68.75
Open     -
Vol / Avg. 0.00/6.02M
Mkt cap 59.58B
P/E 19.00
Div/yield 0.34/2.20
EPS 3.21
Shares 959.35M
Beta 0.58
Inst. own 55%
Jul 29, 2015
Q2 2015 Teva Pharmaceutical Industries Ltd Earnings Release (Estimated) - 7:00AM EDT - Add to calendar
May 13, 2015
Teva Pharmaceutical Industries Ltd at Bank of America Merrill Lynch Health Care Conference
Apr 30, 2015
Q1 2015 Teva Pharmaceutical Industries Ltd Earnings Call - Webcast
Apr 30, 2015
Q1 2015 Teva Pharmaceutical Industries Ltd Earnings Release
Mar 30, 2015
Teva Pharmaceutical Industries Ltd Reinforces Leadership Position in CNS with Acquisition of Auspex - Webcast
Mar 17, 2015
Q4 2014 Ignyta Inc Earnings Call and to Discuss Acquisition by Ignyta of Four Oncology R&D Assets from Teva - Webcast
Mar 12, 2015
Teva Pharmaceutical Industries Ltd at Barclays Healthcare Conference
Mar 3, 2015
Teva Pharmaceutical Industries Ltd at Cowen Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 9.09% 15.03%
Operating margin 15.03% 19.49%
EBITD margin - 29.59%
Return on average assets 3.89% 6.49%
Return on average equity 7.79% 13.32%
Employees 43,009 -
CDP Score - 89 B


5 Basel St., P.O. Box 3190
+972-3-9267267 (Phone)
+972-3-9234050 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha


Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva’s active pharmaceutical ingredient (API) business provides vertical integration to Teva’s own pharmaceutical production. The Company’s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. In July 2014, it acquired Labrys.

Officers and directors

Yitzhak Peterburg Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Erez Vigodman President, Chief Executive Officer, Director
Age: 55
Bio & Compensation  - Reuters
Amir Elstein Vice Chairman of the Board
Age: 59
Bio & Compensation  - Reuters
Eyal Desheh Group Executive Vice President, Chief Financial Officer
Age: 62
Bio & Compensation  - Reuters
Carlo De Notaristefani Ph.D. President and Chief Executive Officer, Global Operations
Age: 57
Bio & Compensation  - Reuters
Robert Koremans M.D. President, Chief Executive Officer - Global Specialty Medicines
Age: 53
Bio & Compensation  - Reuters
Sigurdur Oli. Olafsson President and Chief Executive Officer - Global Generic Medicines Group
Age: 46
Bio & Compensation  - Reuters
Richard S. Egosi Group Executive Vice President, Chief Legal Officer and Company Secretary
Age: 52
Bio & Compensation  - Reuters
Isaac Abravanel Group Executive Vice President - Teva Corporate in Israel and Global Community Alliances
Age: 59
Bio & Compensation  - Reuters
Iris Beck-Codner Group Executive Vice President - Corporate Marketing Excellence and Communication
Age: 49
Bio & Compensation  - Reuters